India, April 21 -- Dishman Carbogen Amcis announced that its Shanghai facility has successfully obtained its first Drug Manufacturing License (DML) from China's National Medical Products Administration (NMPA).The NMPA approval followed a rigorous review focused on GMP compliance and operational readiness. The Shanghai site successfully met all regulatory expectations, reflecting the maturing of its operations and the strength of its quality systems. This milestone marks a pivotal step in CARBOGEN AMCIS' expansion in China and reinforces its commitment to customers in the region.Located in the Shanghai Chemical Industry Park (SCIP), the 40,000m' site is a fully self-supporting facility equipped for early-phase research and development, pilot...